 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...2122232425262728293031...208209» |
- Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
Effects of Henagliflozin on Cardiac Structure in Patients with Heart Failure with Preserved Ejection Fraction Undergoing Dialysis: The HELD-HF Randomized Controlled Trial (Room 351D, Convention Center) - Oct 18, 2025 - Abstract #KIDNEYWEEK2025KIDNEY_WEEK_2105;
P=N/A
The incidence of adverse events was similar between the two groups (35.7% in the henagliflozin group and 32.1% in the placebo group). Conclusion Henagliflozin significantly reduced LVMI compared with placebo in patients with HFpEF on dialysis and was safe over 24 weeks of treatment.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Longitudinal profiling of cerebrospinal fluid N-glycome dynamics in glioblastoma patients treated with apatinib. (Pubmed Central) - Oct 17, 2025
These shifts correlate with attenuated immunosuppressive signatures, suggesting enhanced immunomodulation that may contribute to apatinib's therapeutic efficacy. This work uncovers the remodeling of the CSF glycome driven by apatinib, providing a novel molecular lens for understanding its anti-angiogenic/immune-modulating mechanisms and proposing CSF N-glycans as dynamic biomarkers for treatment efficacy in GBM.
- | AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
Clinical, Journal, Real-world evidence: Real-world multicenter study of rezvilutamide plus androgen deprivation therapy in Chinese patients with high-volume metastatic hormone-sensitive prostate cancer. (Pubmed Central) - Oct 17, 2025
Rezvilutamide plus ADT provides rapid and profound PSA responses with a favorable safety profile in real-world Chinese patients with high-volume mHSPC. Baseline PSA serves as an important predictor for short-term biochemical response, supporting its clinical value as a standard first-line therapy.
- | Opdivo (nivolumab) / Ono Pharma, BMS, plinabulin (BPI 2358) / BeyondSpring
Trial completion date, Trial primary completion date: Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Oct 16, 2025
P1, N=18, Active, not recruiting, Sponsor: Lyudmila Bazhenova, M.D.
Baseline PSA serves as an important predictor for short-term biochemical response, supporting its clinical value as a standard first-line therapy. Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Jul 2022 --> Nov 2024
- | Itari (linperlisib) / Shanghai YingLi Pharma
Preclinical, Journal: In vitro antitumor effects of PI3K inhibitor linperlisib (YY-20394) on acute myeloid leukemia cells. (Pubmed Central) - Oct 16, 2025
Interestingly, YY20394 did not exert its anti-leukemic effects through modulation of the PI3?K/Akt/mTOR Signaling pathway, suggesting that alternative molecular mechanisms may be involved. YY20394 has a favorable inhibitory effect and significant pro-apoptotic effect on the proliferation of AML cells, which suggests that it has some potential for the treatment of AML.
- | epinephrine / Generic mfg., remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Biomarker, Retrospective data, Journal: New Application of Remimazolam Tosilate in ICU Ventilation: Benefits in Reducing Iatrogenic Stress and Maintaining Stable Immune Function. (Pubmed Central) - Oct 16, 2025
Compared with propofol, remimazolam tosilate may offer potential benefits in mitigating iatrogenic stress and preserving immune homeostasis, while ensuring adequate sedation during ICU mechanical ventilation. It could be a promising sedative agent for use in the ICU setting.
- || carboplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, albumin-bound paclitaxel / Generic mfg.
Journal, Adverse events: Case Report: A case of reversible pulmonary bullae induced by camrelizumab: a new immune-related adverse event. (Pubmed Central) - Oct 16, 2025
This case suggests that pulmonary bullae may represent a rare pulmonary irAE associated with camrelizumab. It provides new clinical insights into immune-related pulmonary complications and offers a valuable reference for the management of similar cases.
- AiRuiKa (camrelizumab) / HLB Bio Group
Clinical protocol, Journal: Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomised controlled trial (PALACE-3). (Pubmed Central) - Oct 16, 2025
P3
gov/study/NCT06339060. The current protocol version number is V.2.0, and the protocol date is 30 June 2024.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Prognostic Value of Clinical and CT Features in Camrelizumab Plus Apatinib Treatment for Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Oct 15, 2025
Clinical and contrast-enhanced show significant prognostic value in patients receiving Camrelizumab plus Apatinib. The developed models may assist in identifying responsive patients and personalizing treatment strategies.
- AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
FLUZOPARIB COMBINED WITH ORAL ETOPOSIDE IN ALTERNATING MAINTENANCE THERAPY FOR NEWLY DIAGNOSED ADVANCED OVARIAN CANCER (FARE TRIAL): A PROSPECTIVE, SINGLE-ARM, PHASE II STUDY (E-Poster Stations) - Oct 15, 2025 - Abstract #IGCS2025IGCS_801;
Among them, 5 patients (35.7%) were diagnosed with FIGO IV Stage, and 9 patients (64.3%) with FIGO III Stage. Median follow-up duration was 26.5 months.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
DALPICICLIB COMBINED WITH NONSTEROIDAL AROMATASE INHIBITORS IN ESTROGEN RECEPTOR-POSITIVE RECURRENT/METASTATIC OVARIAN CANCER AND UTERINE NEOPLASMS: UPDATED RESULTS FROM A SINGLE-CENTER, SINGLE-ARM TRIAL (E-Poster Stations) - Oct 15, 2025 - Abstract #IGCS2025IGCS_764;
P2
17th, 2025), 30 pts with a median of one prior therapy for advanced disease were enrolled, including 9 with low-grade serous ovarian carcinoma (LGSOC), 12 with uterine EC, 8 with low-grade endometrial stromal sarcoma (LGESS) and 1 with uterine leiomyosarcoma (LMS). Twenty-five pts had received ?1 efficacy assessment, and 76.0% achieved 12wPFS.
- AiRuiKa (camrelizumab) / HLB Bio Group
NEOADJUVANT CHEMOIMMUNOTHERAPY COMBINED WITH SURGERY VERSUS CONCURRENT CHEMORADIOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER: A MULTICENTER RANDOMIZED PHASE II/III TRIAL (E-Poster Stations) - Oct 15, 2025 - Abstract #IGCS2025IGCS_727;
P2, P2/3
Twenty-five pts had received ?1 efficacy assessment, and 76.0% achieved 12wPFS. In NACI arm, patients receive one cycle of priming chemotherapy (nab-paclitaxel 260 mg/m
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Clinical, Journal: Efficacy of Different Doses of Remimazolam Tosilate Combined with Esketamine in Painless Abortion Patients: A Prospective, Double-Blind, Randomized Controlled Trial. (Pubmed Central) - Oct 14, 2025
No significant differences were observed among groups for ?HR, induction time, surgical duration, hypertension, body movement, injection pain, postoperative pain, or patient/surgeon/anesthesiologist satisfaction. Low-dose RT (0.2?mg/kg) combined with esketamine significantly shortens recovery and discharge times, ensures hemodynamic stability, and reduces adverse events, making it the recommended sedation strategy for painless abortion procedures.
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Oncology, AiRuiKa (camrelizumab) / HLB Bio Group
Risk of Immune-related adverse events with immune checkpoint inhibitors in locally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials. (Level 2' Exhibit Hall D; In-Person Only) - Oct 13, 2025 - Abstract #AACRNCIEORTC2025AACR_NCI_EORTC_587;
The phase II trial assessed neoadjuvant and adjuvant toripalimab vs placebo, with a 2:1 randomization before and after chemoradiotherapy...This study revealed that patients with LA NPC treated with ICIs in addition to CRT have a higher risk of developing irAEs in general compared to those treated with standard therapy. Early detection of these AEs and providing the appropriate supportive care is essential to optimize the outcomes and maintain patients' quality of life and compliance.
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Oncology, AiRuiKa (camrelizumab) / HLB Bio Group
Toxicity profile of immune checkpoint inhibitors in locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of general and hematologic adverse events from phase II and III randomized trials (Level 2' Exhibit Hall D; In-Person Only) - Oct 13, 2025 - Abstract #AACRNCIEORTC2025AACR_NCI_EORTC_341;
No significant differences were observed in gastrointestinal or constitutional toxicities. These findings support the tolerability of ICIs when integrated into standard treatment regimens.
- | Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Long-term survival after targeted therapy plus immunotherapy without chemotherapy in advanced gallbladder carcinoma: a case report and literature review. (Pubmed Central) - Oct 13, 2025
We report a case of a 59-year-old woman with stage IVA GBC who was unable to tolerate first-line gemcitabine and cisplatin due to severe adverse effects...Based on a multidisciplinary team assessment, she received camrelizumab (PD-1 inhibitor) plus apatinib (VEGFR2 inhibitor)...Following isolated cervical lymph node metastasis, combination therapy with camrelizumab and surufatinib resulted in complete remission...This case highlights the promising potential of targeted therapy and immunotherapy in converting unresectable GBC to operable disease and achieving durable remission, even in patients lacking classic immunotherapy biomarkers. Personalized, non-chemotherapy-based strategies may offer viable alternatives for selected patients.
- | Review, Journal, PARP Biomarker: Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance. (Pubmed Central) - Oct 13, 2025
Additionally, advanced sequencing technologies and resistance research models should be leveraged to identify novel therapeutic targets and improve drug delivery efficiencies. These advancements hold the potential to overcome NHT resistance and significantly enhance the management and prognosis of patients with advanced prostate cancer.
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Biomarker, P2 data, Journal: Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2-Negative Luminal B Breast Cancer: A Prospective, Single-Center, Single-Arm, Phase II Trial (DANCER). (Pubmed Central) - Oct 13, 2025
P2
A novel baseline response index combining CCL4 and pRb showed excellent predictive performance and stratified patients by likelihood of clinical benefit, with ctDNA dynamics further refining stratification. These findings support DAL-AI as a promising neoadjuvant option and highlight the value of biomarker-guided strategies for treatment optimization.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, Real-world evidence: Real-world investigation for camrelizumab combined with apatinib in patients with advanced hepatocellular carcinoma. (Pubmed Central) - Oct 13, 2025
Additionally, extrahepatic metastasis could be associated with worse OS in these patients. Nevertheless, due to the small sample size, retrospective and single-arm study design in the current study, further study with a larger sample size, prospective, controlled design is required.
- || metformin / Generic mfg., HR17031 / Jiangsu Hengrui Pharma, long acting basal insulin (INS068) / Jiangsu Hengrui Pharma
P2 data, Journal: Efficacy and safety benefits of HR17031, a fixed-ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open-label, randomised, parallel three-arm, treat-to-target trial. (Pubmed Central) - Oct 12, 2025
Nevertheless, due to the small sample size, retrospective and single-arm study design in the current study, further study with a larger sample size, prospective, controlled design is required. HR17031 is effective and well-tolerated in patients with type 2 diabetes uncontrolled on metformin with or without a second oral antidiabetic drug.
- | plinabulin (BPI 2358) / BeyondSpring
Journal, Checkpoint inhibition: Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers. (Pubmed Central) - Oct 11, 2025
P1/2
HR17031 is effective and well-tolerated in patients with type 2 diabetes uncontrolled on metformin with or without a second oral antidiabetic drug. These preliminary results provide a rationale for testing RT/plinabulin/ICI combination in future post-ICI-failure confirmatory trials.
- | Journal: New molecules in the therapy of chronic graft-versus-host disease. (Pubmed Central) - Oct 10, 2025
Expanding therapeutic options in cGvHD require decision-making based on organ involvement, prior therapy, and tolerability. Emerging compounds offer the potential to modulate chronic inflammation and fibrosis more precisely, supporting a move toward personalized and combinatorial approaches in advanced-line settings.
- | Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD), AiRuiKa (camrelizumab) / HLB Bio Group
Clinical, Retrospective data, Review, Journal: Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLC. (Pubmed Central) - Oct 9, 2025
This meta-analysis highlights how the efficacy of ICIs in advanced NSCLC varies by age and PS. These findings support a tailored approach to immunotherapy and emphasize the need for trials specifically targeting frail and elderly populations.
- || GSK5784283 / GSK
New P2 trial: A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis (clinicaltrials.gov) - Oct 8, 2025
P2, N=20, Not yet recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
- | AiRuiKa (camrelizumab) / HLB Bio Group, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma, docetaxel / Generic mfg.
Journal, Real-world evidence: Clinical evaluation of combined programmed cell death protein 1 inhibitor and poly(ADP-ribose) polymerase inhibitor in metastatic castration-resistant prostate cancer patients: Insights from a real-world study. (Pubmed Central) - Oct 8, 2025
None of the patients discontinued treatment because of treatment-related AEs. This real-world study demonstrated that the combination of a PD-1 inhibitor and PARPi exhibited sustained antitumor activity with an acceptable safety profile in the fourth-line treatment of patients with mCRPC.
- Comparative Evaluation of First-Line Immunotherapy Regimens in Advanced HCC: A NNT- (Number Needed to Treat) and NNH- (Number Needed to Harm) Based Analysis (Convention Center: Hall DE 3118-3334 Posters) - Oct 7, 2025 - Abstract #AASLD2025AASLD_2564;
At 18 and 24 months, the most favorable regimens in terms of NNT were: camrelizumab/rivoceranib: NNT = 6.4 (18 months), 8.1 (24 months); atezolizumab/bevacizumab: NNT = 8.3 (18 months), 9.0 (24 months) and durvalumab/tremelimumab: NNT = 13.9 (18 months), 12.7 (24 months). Based on NNH, the regimens with the most favorable safety profiles were: tislelizumab: NNH =
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Neoadjuvant immuno-chemotherapy versus neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. (Pubmed Central) - Oct 7, 2025
NICE offers better survival than CROSS with similar recurrence patterns. Adjuvant immunotherapy might be an important factor for long-term benefits in residual pathological disease after NICE.
- | golidocitinib (DZD4205) / Dizal Pharma, Tazverik (tazemetostat) / Ipsen, Itari (linperlisib) / Shanghai YingLi Pharma
New P1/2 trial: Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov) - Oct 6, 2025
P1/2, N=48, Not yet recruiting, Sponsor: Ruijin Hospital
- SHR-1918 / Jiangsu Hengrui Pharma, Evkeeza (evinacumab-dgnb) / Regeneron
ANGPTL3 Targeting Monoclonal Antibodies Lead to Robust Reductions in LDL-C, Triglycerides, ApoB, and Non-HDL-C in Dyslipidemic Patients: A Meta-Analysis of 5 Randomized Controlled Trials (Population Science Zone) - Oct 6, 2025 - Abstract #AHA2025AHA_10491;
monoclonal antibodies targeting ANGPTL3 encompassing both evinacumab and the newer agent SHR-1918 consistently reduced LDL-C, triglycerides, and related lipid markers with a favourable tolerability profile. Further large, long-term studies are needed to fully establish their safety, clinical effectiveness, and potential to improve cardiovascular outcomes.
- SHR-1918 / Jiangsu Hengrui Pharma
SHR-1918, an Angiopoietin-Like 3 Antibody, in Patients With Suboptimally Controlled Hyperlipidemia (211-213) - Oct 6, 2025 - Abstract #AHA2025AHA_9072;
8 (26.7%) patients had SHR-1918-related TEAEs. There were no TEAEs leading to treatment discontinuation or death during the study.ConclusionSHR-1918 further reduced LDL-C and TG levels in hyperlipidemic patients on standard lipid-lowering therapies, providing a novel and safe treatment option for hyperlipidemia.
- recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
Immunogenicity of Recaticimab Does Not Impact Its Efficacy in Patients with Dyslipidemia: A Pooled Analysis of Three Phase III and One Phase Ib/II Studies (Clinical Science Zone 2' Moderated Digital Poster 21) - Oct 6, 2025 - Abstract #AHA2025AHA_6071;
P1/2
ADA+ and Nab+ patients had a higher incidence of self-resolving injection site reactions compared to ADA- patients. These findings support the clinical use of recaticimab for lipid-lowering therapy, regardless of immunogenicity status.
- | Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
Journal: Case Report: A chronic myeloid leukemia patient with e8a2 BCR::ABL1 fusion transcript was successfully treated with Flumatinib. (Pubmed Central) - Oct 6, 2025
This report described a CML patient with a rare e8a2 BCR::ABL1 transcript variant, who also presented with difficult-to-correct iron-deficiency anemia. The patient was treated with Flumatinib and achieved complete hematologic remission at 1 month, complete cytogenetic remission at 3 months, and major molecular remission at 6 months.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal, pMMR: Integrating Single-Cell Transcriptomic Data of Metastatic Gastric Cancer to Construct a Tumor-Associated Neutrophil Signature and Clinical Validation in MSS/pMMR Patients. (Pubmed Central) - Oct 6, 2025
Additionally, we assessed chemotherapy and targeted drug sensitivities and identified small-molecule compounds targeting the six prognostic genes. This study highlights the significance of TANs in predicting GC prognosis, immunotherapy response, and drug exploration, providing a foundation for personalized treatment strategies.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A case report of hepatocarcinoma-originated pericardial malignancy. (Pubmed Central) - Oct 6, 2025
Serial contrast-enhanced computed tomography of the thorax and abdomen demonstrated progressive metastatic dissemination with malignant pleural and peritoneal effusion formation. Despite therapeutic intervention, the patient ultimately experienced disease progression culminating in mortality.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, Journal, Real-world evidence: Pyrotinib versus Pertuzumab with Trastuzumab and Taxane in HER2-Positive Metastatic Breast Cancer: A Chinese Multicenter Real-world Study. (Pubmed Central) - Oct 5, 2025
While THPy demonstrates a higher ORR and a trend toward longer PFS, it also carries a higher incidence of adverse events, particularly diarrhea. These findings offer preliminary insights that may help inform treatment decisions, pending further validation in prospective studies.
- AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant chemo-immunotherapy with camrelizumab plus chemotherapy in resectable or potentially resectable locally advanced head and neck squamous cell carcinoma: an open-label, single-arm, phase II trial (Hall 402) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_1350;
P2
This encouraging result promotes us to continue this phase ? study.
- Tevimbra (tislelizumab-jsgr) / BeOne Medicines, Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
Survival benefits of immune checkpoint inhibitor plus chemotherapy as first-line treatment for squamous non-small cell lung cancer in the Chinese national medical insurance list: A Bayesian network meta-analysis (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_1214;
study. Considering the PFS and OS benefits of camrelizumab plus chemotherapy as first-line treatment for sqNSCLC, it may be regarded as a preferred therapeutic option.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Interim analysis of adebrelimab plus famitinib as later-line treatment for extensive-stage small cell lung cancer: A phase II clinical trial (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_1179;
P=N/A
Considering the PFS and OS benefits of camrelizumab plus chemotherapy as first-line treatment for sqNSCLC, it may be regarded as a preferred therapeutic option. Adebrelimab combined with famitinib showed promising survival benefits with manageable toxicity in relapsed ES-SCLC, particularly in heavily pretreated pts and those with prior immunotherapy exposure.
- Clinical outcomes and safety of continuous immunotherapy and anti-angiogenic combination therapy beyond progression in patients with extensive-stage small cell lung cancer: A retrospective real-world study (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_1172;
Continuous immunotherapy beyond progression in ES-SCLC demonstrates a trend toward prolonged second-line PFS, but does not improve the overall survival. In the second-line treatment, chemotherapy remains an indispensable cornerstone.
- AiRuiKa (camrelizumab) / HLB Bio Group
Thalidomide for prevention of camrelizumab-induced RCCEP in advanced NSCLC: A multicenter real-world study (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_1170;
P4
Prophylactic thalidomide was associated with a reduced overall incidence and severity of RCCEP in patients receiving camrelizumab-based therapy for advanced NSCLC, with a favorable safety profile. These findings support its potential utility in routine clinical practice to improve treatment tolerability.
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced oesophageal squamous cell carcinoma: 3-year follow-up from the phase II trial (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_1060;
P=N/A
Here we report results with 3-year follow-up. Eligible patients with clinical stage T2-4aN0M0, T1-4aN+M0 OSCC were screened and enrolled, treated with regimen of docetaxel (75mg/m2, days 1), carboplatin (AUC=5-6, day 1), camrelizumab (200 mg, day 1) of two 21-day cycles and underwent surgery within 4
- abiraterone acetate / Generic mfg.
Radiotherapy combined with fluzopanib and abiraterone acetate tablets (II) treatment for mCRPC (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_695;
P2
This multicenter, open-label, single-arm, phase II clinical study conducted in China included 40 previously untreated mCRPC (metastatic castration-resistant prostate cancer) patients aged ?18 years. This study is currently in active enrollment stage.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib for conversion treatment of potentially resectable, locally advanced biliary tract cancers: A single-arm, exploratory clinical study (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_667;
P2
This study is currently in active enrollment stage. HAIC consisted of infusions of gemcitabine (1000 mg for 2 hours) and cisplatin (37.5 mg/m2 for two doses, 24 hours apart, 2 hours each time)
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab combined with Celecoxib and chemotherapy as first-line treatment for PD-L1-positive and HER2-negative locally advanced gastric/gastroesophageal junction adenocarcinoma: A single-arm, exploratory clinical trial (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_665;
P4
The secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, and safety. Exploratory endpoints included the correlation between COX-2 expression and treatment efficacy and prognosis, as well as the association of cytokines IL-6, IL-8, and IL-10 with efficacy and prognosis.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Neoadjuvant Adebrelimab plus SOX and Nab-paclitaxel in Resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: A multicentre, single-arm, prospective phase II trial (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_664;
P2, P3
The KEYNOTE-585 study reported that the neoadjuvant and adjuvant pembrolizumab plus cisplatin-based chemotherapy group achieved a higher pathological complete response rate than the placebo plus cisplatin-based chemotherapy group...The primary endpoint is the pathological complete response rate. Secondary research endpoints include: major pathologic response, objective response rate, R0 resection rate, disease-free survival, overall survival, and safety.
- AiTan (rivoceranib) / HLB Bio Group
Efficacy of transarterial chemoembolization with and without apatinib in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_650;
Compared with TACE alone, TACE combined with apatinib can significantly improve overall survival, objective response rate, and disease control rate in patients with intermediate- to advanced-stage HCC and should be recommended for suitable candidates with unresectable HCC. However, further well-designed RCTs are needed to confirm these findings and assess long-term safety and quality-of-life outcomes.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Phase II study of adebrelimab combined with apatinib and nab-paclitaxel as second-line therapy in patients with advanced gastric cancer previously treated with immunotherapy (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_634;
P2
The combination of Adebrelimab, Apatinib, and nab-Paclitaxel demonstrated modest efficacy and manageable safety as second-line treatment of advanced gastric cancer, representing a potential new option. Further randomized controlled trials are warranted to confirm the long-term efficacy and safety of this regimen.
- Comparative pathologic complete response of neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors in locally advanced gastric or gastroesophageal junction adenocarcinoma: A systematic review and Bayesian network meta-analysis (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_599;
Further randomized controlled trials are warranted to confirm the long-term efficacy and safety of this regimen. Moderate effects were seen with Camrelizumab + NCT (OR 4.65, CrI: 1.72
- Sulanda (surufatinib) / Hutchmed
Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: Results from phase II part of a randomized, open-label, active-controlled, phase II/III study (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_557;
P2/3
The safety profile is manageable. The tetrad regimen may emerge as a new frontline option for the targeted population.
- Tevimbra (tislelizumab-jsgr) / BeOne Medicines, Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
Reduced-intensity CRT plus PD-1 inhibitor for elderly ESCC: A retrospective cohort (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_522;
P
The tetrad regimen may emerge as a new frontline option for the targeted population. We tested a triple-optimised regimen